N
ABEO icon

Natixis’s Abeona Therapeutics ABEO Stock Holding History

Natixis’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$116K Buy
+19,631
New +$108K ﹤0.01% 986

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OIA
OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Natixis's ABEO Position: Q2 2026 in Review

Natixis opened a new position in Abeona Therapeutics (ABEO) in Q2 2026: 19,631 shares worth $116K. The stake represents ﹤0.01% of the portfolio and ranks #986 among its holdings.

127 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

  • Natixis held 19,631 shares of Abeona Therapeutics worth $116K as of Q2 2026.
  • Abeona Therapeutics was a new Natixis position in Q2 2026.
  • Abeona Therapeutics made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #986 holding.
  • 127 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.